Literature DB >> 18948169

Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.

M D Siegelin1, A Habel, T Gaiser.   

Abstract

EGCG is a flavonoid that exhibited therapeutic activity in cancer. In this study three glioblastoma cell lines (U87, A172 and U251) were treated with EGCG, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or the combination of both. Treatment with subtoxic doses of EGCG in combination with TRAIL induces rapid apoptosis in TRAIL-resistant glioma cells, suggesting that this combined treatment may offer an attractive strategy for treating gliomas. EGCG treatment down-regulated phosphoprotein-enriched in astrocytes (PEA15) through an Akt (PKB)-dependent mechanism. In addition, over-expression of PEA15 attenuated cytotoxicity induced by the combination of EGCG and TRAIL. In summary, PEA15 is a key regulator in TRAIL-EGCG-mediated cell death in malignant glioma.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18948169     DOI： 10.1016/j.neulet.2008.10.036

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  10 in total

Review 1.  Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

Authors:  Guillaume Jacquemin; Sarah Shirley; Olivier Micheau
Journal:  Cell Mol Life Sci       Date:  2010-05-29       Impact factor: 9.261

2.  Epigallocatechin-3-gallate induces apoptosis, inhibits proliferation and decreases invasion of glioma cell.

Authors:  Hong Li; Zhe Li; Ya-Ming Xu; Yue Wu; Kang-Kang Yu; Can Zhang; Yong-Hua Ji; Gang Ding; Fu-Xue Chen
Journal:  Neurosci Bull       Date:  2013-12-13       Impact factor: 5.203

3.  Characterization of a MAPK scaffolding protein logic gate in gonadotropes.

Authors:  Soon Gang Choi; Frederique Ruf-Zamojski; Hanna Pincas; Badrinath Roysam; Stuart C Sealfon
Journal:  Mol Endocrinol       Date:  2011-03-24

4.  MicroRNA-132 targets PEA-15 and suppresses the progression of astrocytoma in vitro.

Authors:  Fei Geng; Jian-Lin Wu; Gui-Feng Lu; Zhi-Ping Liang; Zhuo-Li Duan; Xi Gu
Journal:  J Neurooncol       Date:  2016-06-13       Impact factor: 4.130

5.  EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer.

Authors:  Su-Ni Tang; Junsheng Fu; Sharmila Shankar; Rakesh K Srivastava
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

6.  Epigallocatechin 3-gallate ameliorates bile duct ligation induced liver injury in mice by modulation of mitochondrial oxidative stress and inflammation.

Authors:  Kezhen Shen; Xiaowen Feng; Rong Su; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

Review 7.  Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer.

Authors:  Saleh A Almatroodi; Ahmad Almatroudi; Amjad Ali Khan; Fahad A Alhumaydhi; Mohammed A Alsahli; Arshad Husain Rahmani
Journal:  Molecules       Date:  2020-07-09       Impact factor: 4.411

Review 8.  Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states.

Authors:  Fiona H Greig; Graeme F Nixon
Journal:  Pharmacol Ther       Date:  2014-03-20       Impact factor: 12.310

Review 9.  EGCG Mediated Targeting of Deregulated Signaling Pathways and Non-Coding RNAs in Different Cancers: Focus on JAK/STAT, Wnt/β-Catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL Mediated Signaling Pathways.

Authors:  Ammad Ahmad Farooqi; Marina Pinheiro; Andreia Granja; Fulvia Farabegoli; Salette Reis; Rukset Attar; Uteuliyev Yerzhan Sabitaliyevich; Baojun Xu; Aamir Ahmad
Journal:  Cancers (Basel)       Date:  2020-04-12       Impact factor: 6.639

Review 10.  Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas.

Authors:  Francesca Persano; Giuseppe Gigli; Stefano Leporatti
Journal:  Int J Mol Sci       Date:  2022-03-20       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.